VIDEO: Older IBD patients use more aminosalicylate monotherapy
Click Here to Manage Email Alerts
In this exclusive video, Edward L. Barnes, MD, MPH, from The University of North Carolina at Chapel Hill, discussed a study comparing the use of aminosalicylate monotherapy in older vs. younger patients with inflammatory bowel disease.
Barnes and colleagues collected data from the TARGET-IBD multicenter, observational cohort.
He said patients aged 65 years or older were significantly more likely than younger patients to use aminosalicylate monotherapy.
“We know that the prevalence of IBD is going to continue to increase as our aging population with Crohn’s disease and ulcerative colitis increases,” Barnes said. “It is important to understand medications are being used to treat those patients that are older with IBD, particularly the patients that are above age 65. We don’t necessarily think patients that are older have less severe Crohn’s disease or ulcerative colitis thus it’s important to understand while we use appropriate medications and achieve the appropriate outcomes among patients with Crohn’s disease and ulcerative colitis and not just assume that because patients are diagnosed when they are older or treated at an older age that we should be using therapies not as effective.”
He noted the study allowed he and his colleagues to look at unique medication patterns in patients with Crohn’s disease and ulcerative colitis and comparisons between older vs. younger patients and their medication use patterns.
Collapse
Click Here to Manage Email Alerts